CASE DISCUSSION

Pharmacological Therapy For Osteoarthritis

Presented from India by Dr. Shanmuganandan Krishnan

Likes

2506

Views

100

Bookmarks

Case Description

Osteoarthritis, the most common form of arthritis, is a degenerative joint disorder characterized by the gradual deterioration of joint cartilage and the underlying bone. It often affects weight-bearing joints such as the knees, hips, and hands, leading to pain, stiffness, and reduced joint...

Case Summary

Osteoarthritis (OA) affects a significant portion of the population, particularly those over 60, with prevalence rates varying between countries. While surgery remains a primary treatment option, patient acceptance is often limited due to mobility and mortality concerns associated with knee replacement. Understanding the pathobiology of OA, which involves a combination of degeneration, inflammation, and cytokine activity leading to cartilage destruction, is crucial for developing effective pharmacological interventions.

Speaker Profile

Dr. Shanmuganandan Krishnan

Professor SBMCH, Consultant Rheumatology, Apollo Hospitals, Chennai

Brig (Prof.) Krishnan. Shanmuganandan, a distinguished medical professional, brings over 30 years of extensive teaching and clinical experience to the field of medicine. With a robust academic background including an MBBS and MD in Medicine from AFMC, as well as specialized training in Rheumatology, HIV Medicine, and Health Research Methodology, he has continuously contributed to medical education and research. Currently serving as a Professor at SBMCH/BIHER and a Consultant Rheumatologist at prestigious institutions such as Apollo Hospitals and Rela Hospitals in Chennai, Dr. Shanmuganandan excels in clinical problem-solving and diagnosis. His expertise extends to digital health, biosimilar use, immunoinflammatory syndromes, and post-COVID hyperinflammatory immune syndromes. A recipient of commendation medals and awards, he has also been actively involved in editorial roles, MCI assessment, and various professional associations, showcasing his commitment to advancing medical knowledge and healthcare practices in India.

Disclosures

Assimilate requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships for anyone with the ability to control the content of this educational activity have been reviewed and mitigated. Others involved in the planning of this activity have no relevant financial relationships.